Table 2.
Treatment-related grade ≥3 nonhematologic adverse events after pembrolizumab
| Toxicity | Number (total %) |
|---|---|
| Electrolyte abnormalities | |
| Hypokalemia | 1 (3%) |
| Hepatic | |
| ALT increase | 2 (5%) |
| AST increase | 2 (5%) |
| Alkaline phosphatase increase | 2 (5%) |
| Lymphocytic infiltration of liver | 1 (3%) |
| Infections | |
| Catheter-related infection | 3 (8%) |
| Clostridium difficile colitis | 1 (3%) |
| Febrile neutropenia | 23 (62%) |
| Hepatic infection | 1 (3%) |
| Lung infection | 10 (26%) |
| Typhlitis | 1 (3%) |
| Pulmonary | |
| Pulmonary edema | 1 (3%) |
| Skin | |
| Maculopapular rash | 2 (5%) |
NOTE: The proportion of grade ≥3 nonhematologic adverse events related to pembrolizumab is shown in this table.